Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer

Patients with measurable or evaluable locally advanced or metastatic squamous cell carcinoma of the oesophagus were treated with cisplatin (CDDP), 100 mg/m 2, combined with 5-fluorouracil (5-FU) at a dose of 1000 mg/m 2 as a continuous infusion from days 1–5 (Arm A) or with CDDP alone (Arm B). Cycle...

Full description

Saved in:

Bibliographic Details
Published in:	European journal of cancer (1990) Vol. 33; no. 8; pp. 1216 - 1220
Main Authors:	Bleiberg, H, Conroy, T, Paillot, B, Lacave, A.J, Blijham, G, Jacob, J.H, Bedenne, L, Namer, M, De Besi, P, Gay, F, Collette, L, Sahmoud, T
Format:	Journal Article
Language:	English
Published:	Oxford Elsevier Ltd 01.07.1997 Elsevier
Subjects:	5-FU Adult advanced Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences cancer Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Chemotherapy cisplatin Cisplatin - administration & dosage Cisplatin - adverse effects Disease Progression Esophageal Neoplasms - drug therapy Esophageal Neoplasms - pathology Female Fluorouracil - administration & dosage Fluorouracil - adverse effects Humans Male Medical sciences Middle Aged oesophageal Pharmacology. Drug treatments squamous cell carcinoma Survival Rate toxicity toxicity advanced cancer oesophageal cisplatin chemotherapy squamous cell carcinoma 5-FU Antineoplastic agent Human Drug Drug combination Squamous cell carcinoma Toxicity Treatment efficiency Esophageal disease Malignant tumor Cisplatin Esophagus Chemotherapy Digestive diseases Complication Advanced stage Fluorouracil
ISSN:	0959-8049, 1879-0852
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!